ストックスクリーナーアプリを入手
24.61
3.49%
0.83
プレマーケット:
25.09
0.48
+1.95%
前日終値:
$23.78
開ける：
$23.95
24時間の取引高:
861.21K
Relative Volume:
0.90
時価総額：
$1.63B
収益：
$9.98M
当期純損益:
$-154.08M
株価収益率:
-9.5388
EPS:
-2.58
ネットキャッシュフロー:
$-159.66M
1週間 パフォーマンス:
+7.28%
1か月 パフォーマンス:
-2.11%
6か月 パフォーマンス:
-33.05%
1年 パフォーマンス:
-38.46%
1日の値動き範囲:
$23.70
$24.91
1週間の範囲:
$22.16
$24.91
52週間の値動き範囲:
$22.16
$53.18
Celldex Therapeutics Inc Stock (CLDX) Company Profile
CLDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
24.61 | 1.63B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-07 | 開始されました | Citigroup | Buy |
| 2024-09-30 | 開始されました | Goldman | Neutral |
| 2024-09-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 開始されました | Stifel | Buy |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2023-12-20 | 開始されました | TD Cowen | Outperform |
| 2023-11-10 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 開始されました | Wells Fargo | Underweight |
| 2021-09-17 | 開始されました | Jefferies | Buy |
| 2021-09-10 | 開始されました | SVB Leerink | Outperform |
| 2021-07-22 | 開始されました | Guggenheim | Buy |
| 2020-02-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-07 | 開始されました | Aegis Capital | Buy |
| 2016-03-08 | ダウングレード | Jefferies | Buy → Hold |
| 2016-03-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2016-03-07 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2016-03-01 | 開始されました | H.C. Wainwright | Buy |
| 2015-08-11 | 繰り返されました | Brean Capital | Buy |
| 2015-08-11 | 繰り返されました | Oppenheimer | Outperform |
| 2015-08-11 | 繰り返されました | ROTH Capital | Buy |
| 2015-06-02 | 繰り返されました | WBB Securities | Strong Buy |
| 2014-11-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2013-07-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-03-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2013-01-10 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2012-10-02 | 繰り返されました | Oppenheimer | Outperform |
| 2012-09-14 | 繰り返されました | Cantor Fitzgerald | Buy |
すべてを表示
Celldex Therapeutics Inc (CLDX) 最新ニュース
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Expands By 10.7% - MarketBeat
Analysts Provide Insight Into Celldex Therapeutics Inc’s (CLDX) Potential. - Stocks Register
B-cell Non-hodgkin Lymphoma Clinical and Non-Clinical - openPR
Celldex stock hits 52-week low at $22.89 amid market challenges By Investing.com - Investing.com South Africa
Celldex stock hits 52-week low at $22.89 amid market challenges - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowHere's What Happened - MarketBeat
Stifel maintains positive outlook on Celldex and Third Harmonic stocks By Investing.com - Investing.com Canada
Jasper’s Briquilimab Stands Up To Competition, But Investors Bail - News & Insights
Guggenheim maintains $90 target on Celldex stock after study By Investing.com - Investing.com Canada
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap UpHere's Why - MarketBeat
Before You Invest, Make Sure You Check This Asset Entities Inc (NASDAQ: ASST) Analysis - Stocks Register
What Do Wall Street Analysts Think About Celldex Therapeutics Inc (NASDAQ: CLDX) Stock? - Stocks Register
Why Is Jasper Therapeutics Stock Trading Lower On Wednesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
Celldex Therapeutics' SWOT analysis: barzolvolimab potential drives stock outlook By Investing.com - Investing.com Canada
Celldex Therapeutics’ SWOT analysis: barzolvolimab potential drives stock outlook By Investing.com - Investing.com Nigeria
Celldex Therapeutics' SWOT analysis: barzolvolimab potential drives stock outlook - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Given “Overweight” Rating at Cantor Fitzgerald - Defense World
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock potential in urticaria By Investing.com - Investing.com Nigeria
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria By Investing.com - Investing.com South Africa
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Drops By 5.1% - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Barclays PLC Has $4.43 Million Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
What Analysts Are Saying About Celldex Therapeutics Stock - Benzinga
Celldex Therapeutics' (CLDX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis - The Manila Times
Celldex Launches Pivotal Phase 2 Trial for Novel Atopic Dermatitis Treatment, Targeting 20% of US Population - StockTitan
State Street Corp Sells 173,932 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential By Investing.com - Investing.com Nigeria
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 5.5%Here's Why - MarketBeat
BNP Paribas Financial Markets Boosts Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
XTX Topco Ltd Makes New $1.56 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Wellington Management Group LLP Acquires 1,167,659 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
The Manufacturers Life Insurance Company Cuts Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Readystate Asset Management LP Takes $6.10 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Redmile Group LLC Cuts Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Cinctive Capital Management LP Decreases Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Position Decreased by Fmr LLC - MarketBeat
Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) PT at $62.25 - MarketBeat
Prurigo Nodularis Pipeline Insights 2024: Therapies, Clinical - openPR
CBC acquires UCB’s neurology and allergy business in China - Pharmaceutical Technology
Bellevue Group AG Buys 100,000 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Intech Investment Management LLC Makes New $871,000 Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Fisher Asset Management LLC Buys 253,808 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics Inc (CLDX) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):